Cereno Scientific engages Carnegie Investment Bank as new Certified Adviser
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced a change of Certified Adviser from Mangold Fondkommission to Carnegie Investment Bank.Cereno Scientific has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on January 1, 2024. Until then, Mangold Fondkommission AB will continue to act as Certified Adviser to the company. For further information, please